Novavax, a small American company buoyed by lavish support from the U.S. government, announced on Monday the results of a clinical trial of its Covid-19 vaccine in the United States and Mexico, finding that its two-shot inoculation provides potent protection against the coronavirus.
In the 29,960-person trial, the vaccine demonstrated an overall efficacy of 90.4 percent, on par with the vaccines made by Pfizer-BioNTech and Moderna, and higher than the one-shot vaccine from Johnson & Johnson. The Novavax vaccine showed an efficacy of 100 percent at preventing moderate or severe disease.
{iframe}https://www.nytimes.com/2021/06/14/health/covid-vaccine-novavax.html?campaign_id=60&emc=edit_na_20210614&instance_id=0&nl=breaking-news&ref=headline®i_id=34889205&segment_id=60630&user_id=8e083dbbf9d0e6d0e8489f19e7d011d2{/iframe}